Data from literature showed that IL-6 reduced the sensitivity to erlotinib in NSCLC cells harboring EGFR mutations, due to an increased autocrine stimulation of the IL-6/gp130/signal transducer and activator of transcription 3 (STAT3) pathway (46). This evidence concerns the gene EGFR and non-small cell lung carcinoma.